secwatch.observer — SEC 8-K summary
======================================

Issuer:     Tvardi Therapeutics, Inc. (TVRD)
CIK:        0001346830
Form:       8-K
Filed at:   2023-11-13T23:59:59+00:00
Accession:  0001104659-23-117212
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cara Therapeutics Q3 2023 net loss $28M; cash runway extended into 2025 via $40M royalty financing
--------------------------------------------------------------------------------

- Q3 total revenue $4.9M, down from $10.8M YoY; net loss $0.52/share vs $0.43/share YoY.
- Cash $83.3M at Sep 30, 2023; entered $40M royalty financing with HealthCare Royalty to extend runway into 2025.
- KORSUVA injection net sales $4.4M; vial orders up 36% QoQ; CMS confirmed TDAPA period until Mar 31, 2024.
- Topline data from KIND 1 Phase 3 atopic dermatitis expected Dec 2023; KICK Phase 3 results in 2H24.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923117212/0001104659-23-117212-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1346830/000110465923117212/tm2330513d2_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-23-117212

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer